Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study

Osteoporosis International

Volumn 27, Issue 5, 2016, Pages 1857-1867

  Coloma, P M ^a   de Ridder, M ^a   Bezemer, I ^b   Herings, R M C ^b   Gini, R ^c   Pecchioli, S ^d   Scotti, L ^e   Rijnbeek, P ^a   Mosseveld, M ^a   van der Lei, J ^a   Trifiro G ^a,f   Sturkenboom, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c Tuscany Regional Health Agency Agenzia Regionale di Sanità della Toscana   (Italy)

^d Società Italiana di Medicina Generale   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bisphosphonates; Cardiac valve disorders; Cardiac valve regurgitation; Drug induced valvular heart disease; Drug induced valvulopathy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; DRUG EXPOSURE; FEMALE; HEART VALVE CALCIFICATION; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; VALVULAR HEART DISEASE; VERY ELDERLY; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG SUBSTITUTION; FACTUAL DATABASE; HEART VALVE DISEASES; ITALY; META ANALYSIS; MIDDLE AGED; NETHERLANDS; PROCEDURES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HEART VALVE DISEASES; HUMANS; ITALY; MALE; MIDDLE AGED; NETHERLANDS; OSTEOPOROSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

EID: 84951837058     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3441-2     Document Type: Article

References (41)

1. O’Connell MB (2006) Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. J Manag Care Pharma: JMCP 12(6 Suppl A):S10–S19, quiz S26-18
2. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150–S162. doi:10.1542/peds.2006-2023H
3. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. doi:10.4065/83.9.1032
4. European Medicines Agency 2011 EudraVigilance-Human Annual Report. Accessible at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/06/WC500144560.pdf (2013)
5. Elmariah S, Delaney JA, O’Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, Halperin JL (2010) Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 56(21):1752–1759. doi:10.1016/j.jacc.2010.05.050
6. d’Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B (2011) Valvular heart disease: the next cardiac epidemic. Heart 97(2):91–93. doi:10.1136/hrt.2010.205096
7. Graham JR, Suby HI, LeCompte PR, Sadowsky NL (1966) Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 274(7):359–368. doi:10.1056/NEJM196602172740701
8. Graham JR (1967) Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 254(1):1–12
9. Misch KA (1974) Development of heart valve lesions during methysergide therapy. Br Med J 2(5915):365–366
10. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL (2000) Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA: J Am Med Assoc 283(13):1703–1709
11. Seghatol FF, Rigolin VH (2002) Appetite suppressants and valvular heart disease. Curr Opin Cardiol 17(5):486–492
12. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE (1998) A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339(11):719–724. doi:10.1056/NEJM199809103391102
13. Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L (2007) Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 64(12):1721–1726. doi:10.1001/archneur.64.12.1721
14. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29–38. doi:10.1056/NEJMoa062222
15. Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf 35(2):159–171. doi:10.2165/11594940-000000000-00000
16. Gueffet JP, Piriou N, Trochu JN (2010) Valvular heart disease associated with benfluorex. Arch Cardiovasc Dis 103(5):342–343. doi:10.1016/j.acvd.2009.09.015
17. Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Marechaux S, Eicher JC, Blanchard-Lemoine B, Rousseau J, Henon P, Jobic Y, Etienne Y (2011) Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Europ J Echocardiograp: J Working Group Echocardiography Europ Soc Cardiol 12(4):265–271. doi:10.1093/ejechocard/jeq172
18. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14(9):773–779
19. Fiore CE, Pennisi P, Pulvirenti I, Francucci CM (2009) Bisphosphonates and atherosclerosis. J Endocrinol Investig 32(4 Suppl):38–43
20. Aksoy O, Cam A, Goel SS, Houghtaling PL, Williams S, Ruiz-Rodriguez E, Menon V, Kapadia SR, Tuzcu EM, Blackstone EH, Griffin BP (2012) Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol 59(16):1452–1459. doi:10.1016/j.jacc.2012.01.024
21. John Camm A (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 32(3):426–436. doi:10.1016/j.clinthera.2010.03.014
22. Grove EL, Abrahamsen B, Vestergaard P (2013) Heart failure in patients treated with bisphosphonates. J Intern Med 274(4):342–350. doi:10.1111/joim.12087
23. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappe DL, Osborn JS, Day JD (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103(6):824–828. doi:10.1016/j.amjcard.2008.11.037
24. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1–11. doi:10.1002/pds.2053
25. Coloma PM, Trifiro G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, van der Lei J, Sturkenboom M (2012) Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. doi:10.1002/pds.3197
26. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23(11):2093–2100
27. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel JH (1999) Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38(4–5):339–344. doi:10.1267/METH99040339
28. Goettsch WG, de Jong RB, Kramarz P, Herings RM (2007) Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf 16(2):166–172. doi:10.1002/pds.1245
29. Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L (2008) Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 19(1):150–155. doi:10.1093/annonc/mdm404
30. Barchielli A, Balzi D, Marchionni N, Carrabba N, Margheri M, Santoro GM, Olivotto I, Buiatti E (2007) Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry. Italy Int J Cardiol 114(1):57–63. doi:10.1016/j.ijcard.2006.01.006
31. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67(1):99–109. doi:10.1111/j.1365-2125.2008.03308.x
32. WHO WHO DDD Classification. http://www.whocc.no/ddd/definition_and_general_considera/
33. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374(9689):577–585. doi:10.1016/S0140-6736(09)60252-X
34. Andrejak M, Tribouilloy C (2013) Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 106(5):333–339. doi:10.1016/j.acvd.2013.02.003
35. Cosyns B, Droogmans S, Rosenhek R, Lancellotti P (2013) Drug-induced valvular heart disease. Heart 99(1):7–12. doi:10.1136/heartjnl-2012-302239
36. Mohler ER 3rd, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH (1999) Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8(3):254–260
37. Elmariah S, Rajamannan NM (2010) Medical therapy for calcific aortic stenosis: the use of bisphosphonates. Cardiology 117(3):229–230. doi:10.1159/000322902
38. Vieira HP, Leite IA, Araujo Sampaio TM, de Dos Anjos PJ, do Nascimento AA, de Abreu LC, Valenti VE, Goulart FC, Adami F (2013) Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med 6(1):24. doi:10.1186/1755-7682-6-24
39. Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, Gold DT, Vansomphone SS, Wei R, O’Malley CD (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24(9):2509–2517. doi:10.1007/s00198-013-2326-5
40. Persy V, D’Haese P (2009) Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 15(9):405–416. doi:10.1016/j.molmed.2009.07.001
41. Dweck MR, Newby DE (2012) Osteoporosis is a major confounder in observational studies investigating bisphosphonate therapy in aortic stenosis. J Am Coll Cardiol 60(11):1027. doi:10.1016/j.jacc.2012.04.048, author reply 1027